Blog

Photo from Mel Mann/LinkedIn

May 11, 2024, 02:47

Mel Mann: Gleevec’s Anniversary

Mel Mann, Patient Advocate in

”Gleevec’s Anniversary.

On 10 May 2001, Gleevec (Imatinib) was approved by the FDA for use in Chronic Myeloid Leukemia (CML) and made the cover of TIME Magazine. It now works for 11 different types of cancer.

I was blessed to enter the Gleevec phase 1 clinical trial when it began 3 years prior, in 1998, and I became the World’s Longest Living Gleevec Survivor. When I was first diagnosed, I was given 3 years to live. However, I was able to get ‘Today’s medicine Yesterday,’ and that 3 years became 30 years. Clinical Trials are a way of getting ‘Tomorrow’s Medicine Today.”’

Mel Mann

Source: Mel Mann/LinkedIn

cancer chronic myeloid leukemia clinical trial CML FDA Gleevec imatinib Mel Mann OncoDaily Oncology Time magazine World’s Longest Living Gleevec Survivor

Mark Ruffalo and Brain Cancer: How He Went Against, How He Survived, and More

Sharon Osbourne and Colon Cancer: How She Went Against, How She Survived, and More

Marcia Cross and Anal Cancer: How She Went Against, How She Survived, and More

Pancreatic Cancer: Symptoms, Causes, Types, Diagnosis & Treatment

FDA approves Methotrexate for Pediatric acute Lymphoblastic Leukemia

Special Coverage